Building a Global BK Community

    Building a Global BK Community

    A conversation about how to build a broader BK community of writers, customers, practitioners, and other stakeholders--with a special focus on the Asia-Pacific Region.

    • jesuzaalex@gmail.com

      Why you should use sales prospecting?

      Created by jesuza alex

      There are a number of different ways in which businesses conduct their sales. You might have adopted various marketing techniques to support your business and there are companies who use more than a single methodology to sell their products and services. Sales prospecting is a crucial point that many companies overlook, not knowing that there are several benefits associated to it. While some people do it just because of the advantages of prospecting, it has actually become a necessity for salespeople and companies as it is critical in retaining customers as well as for the growth and increased revenue. Here, we will take a glance at certain benefits that prospecting brings to you.

      Increased number of clients

      This thing depends largely on how you go about your business and how effectively you use the sales prospecting to your benefit. The gradual attrition is responsible for making a salesperson lose about 15 to 20 percent of the business annually. When you conduct the prospecting, it helps your salespeople to be busy as they are always intact with the new and old clients. Also, it would increase the interest of people in your business and you will eventually have more clients. Moreover, it is a great way of keeping individuals loyal to your business.

      Better revenue

      When you have more number of customers, you will ultimately end up with more sales. Therefore, your business is going to generate more income than it was doing previously. This directly has an impact on the productivity of your business as you are able to enhance the performance of your company and increase your sales. Ultimately, you will end up selling more and everybody will be happy. From the perspective of a salesperson, the better the sales are the more commission there will be.

      Qualified prospects / leads

      When you conduct the sales prospecting, you get a chance to connect to people. It is actually a step in inbound sales where you are hunting for active buyers and you connect with them, hoping that they are interested in a type of product that you are offering. Then, you explore the individual, i.e. ask questions which helps you in knowing the interests of the customer and you get to verify him as a qualified individual. So, you get to know about the needs of the individual, why and how he might purchase, giving you the chance to present your products in front of the person as he is likely to purchase it.

      Data collection

      One of the best things about sales prospecting is that even if it does not give you an immediate sale, there are cases when it will help you in future. You gather data and conduct research which helps in knowing more about the market and where the trend might shape up in coming days. Also, you can use the obtained information about a person and contact him some time in future when he or she will be more ready and interested in purchasing the product you offer.

      Open in a new window

    • alvinaj660@gmail.com

      Meningococcal vaccine market report is in… and top companies are expected to see growth again

      Created by Alvina Jennifer

      The Global Meningococcal Vaccines Market Research Report has analysed the 2013 market and made predictions for the next four years. Key players are expected to continue to lead the industry, but newcomers are not to be ignored.  

      The Global Meningococcal Vaccines Market Research Report was published and outlined the foreseeable growth of the market up until 2022. The report detailed global and regional markets with explanation of expected growth in the meningococcal vaccine industry in particular areas.

      What the report covered


      The report begins with market definitions and an overview of the global market and related technologies. This is followed by an analysis of the market status and global trends, particularly over the past five years. It features data from 2013, estimations from 2014 and 2015 and projections up to 2022.


      The report examines regions including North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. To discuss the market geographically, it is further segmented into countries such as Canada, India, Japan, China and Germany.

      There are many driving factors of the report including:

      • Non-profit organisations taking part in educating and creating awareness around vaccines
      • Travel vaccines for meningococcal
      • Partnerships to support the development of meningococcal vaccines for a lower cost.
      • Betterment of global health, particularly in developing countries.

      Along with restraining factors, such as:

      • Supporting the delivery of meningococcal vaccines via cold chains, leading to a higher cost
      • Unstable epidemiology of the meningococcal disease.

      Results

      Possibly the biggest finding of the report is estimations the Global Meningococcal Vaccines Market is expected to surpass US $4 billion by 2022 and will also expand at a compound annual growth rate (CAGR) of approximately 12 per cent over the next four years. This allows new market opportunities to be identified and promotional plans for the market to be put in place.

      The research report then discusses research and development as well as the demand for new products. The authors reveal the industry’s expected top companies for the upcoming years, accompanied by comprehensive company profiles.

      Notable key players mentioned in the report are:

      • Pfizer
      • JN-International Medical Corporation
      • Novartis International AG
      • GlaxoSmithKline plc
      • Sanofi S.A Inc.
      • Serum Institute of India Ltd.
      • Nuron Biotech.

      While big brands of vaccines themselves include:

      Polysaccharide Vaccines

      • Menomune
      • Mencevax
      • NmVac4
      • Quadri Meningo
      • Bi Meningo.

      Conjugate Vaccines

      • Menactra
      • Menveo
      • NeisVac-C
      • Nimenrix
      • Meningitec
      • Menjugate
      • MenAfriVac
      • NmVac4-DT.

      Combination Vaccines

      • MenHibrix
      • Menitorix.

      Meningococcal Strain B Vaccines

      • Bexsero
      • Trumenba.

      Has there been any change since the report was released?

      Pharmaceutical company Pfizer is already taking action by working with public health officials in Thailand to devise new ways to deploy vaccines amid shortfalls in the nation’s health funding.


      According to Luksanawan Thangpaiboolm, head of the company’s vaccine unit in Thailand and Indochina: “Pfizer believes it can significantly alleviate the problems facing the country’s overstretched health services.”

      In 2017, the $129 billion set aside in Thailand’s Public Health Ministry’s budget did not cover the $142 billion required to meet demand. On the back of this, the Thailand Development Research Institute (TDRI) has issued a warning that the country will need $1.4 trillion for public health in a decade’s time, which it will not be able to acquire.  

      Pfizer has a number of available vaccines it is working to deploy to Thailand, including the new breakthrough vaccination for pneumococcal disease, an illness caused by Streptococcus bacteria. Luksanawan mentioned the vaccine is currently available in hospitals across the country but at the moment, costs associated with administering the drug cannot be reimbursed.

      Will the top companies be able to handle the growth?


      With an expected growth predicted for the top companies, it can only be questioned whether they will be prepared for increased demand. After all, it would not be the first time leaders in the industry have faced a shortage.

      An example is the relatively new vaccine able to protect children against meningococcal strain B, Bexsero. In 2016, pharmaceutical giant GlaxoSmithKline announced the vaccine was in short supply across the globe until early 2017.

      This shortage reportedly led countries, including the United Kingdom and Ireland, to include the Bexsero vaccine as part of their national immunisation programs – but due to the higher demand, the short supply available and the cost, the meningococcal-B vaccine is often reserved for children at increased risk of contracting the disease. According to Dr Ryan Harvey at House Call Doctor, these examples include children who have been exposed to meningococcal at child care or school.

      Conclusion

      The Global Meningococcal Vaccines Market Research Report has reiterated the dominance of the industry’s top companies – but with an increased demand for new products and a risk leaders will struggle meeting predicted growth levels, there is an opening for newcomers to make their mark.

      Open in a new window

    • Johanna Vondeling

      Archive of Writing for Change Workshop Materials

      Created by Johanna Vondeling

      Hi All,

      Here you can find archives of the Writing for Change workshops conducted in Perth and Singapore. 

      Here's a blog about the Perth workshop.

      Here's a link to the promo the Sequoia Group posted on their website about the Singapore workshop.

      Attached are the flyers for both workshops.

      Please feel free to add additional resources to this archive!

      Thanks!

       

      Open in a new window

      1 Reply

    Show More
    Contact Information

    About